Table 3.
Treatment and outcomes of children and adolescents presenting with symptoms and signs of Kawasaki disease during the coronavirus disease 2019 pandemic. Values are numbers (percentages) unless stated otherwise
| Variables | Total |
|---|---|
| Treatment: | |
| Intravenous immunoglobulin (2g/kg) infusion | 21 (100) |
| Intravenous immunoglobulin (2g/kg) retreatment | 5 (24) |
| Steroids (2-10 mg/kg/day) | 10 (48) |
| Aspirin (3-5 mg/kg/day) | 21 (100) |
| Broad spectrum antibiotics | 18 (86) |
| Outcome and serious complications: | |
| Persistent fever 36 hours after end of initial intravenous infusion | 5 (24) |
| Median (range) length of hospital stay (days) | 8 (5-17) |
| Admitted to intensive care unit | 17 (81) |
| Fluid resuscitation | 11 (52) |
| Vasoactive and inotropic agents* | 15 (71) |
| Mechanical ventilation | 11 (52) |
| Death | 0 |
*
Adrenaline, dobutamine, milrinone and/or noradrenaline.